Evaluating the Legal and Market Risks of Tempus AI Amid Ongoing Securities Class Action Lawsuits
Tempus AI's failure to disclose risks in its data licensing agreements with AstraZeneca suggests a breakdown in the “measure” and “manage” phases.
Read the original at AInvest ↗
- Topics
- Legal & CourtsCopyright & IP
- Tracked via
- “AI Failure”